- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
| 3 months-12 years | 13-17 years | |
| Vd | 0,2 l/kg | 0,16 l/kg |
| T½ | 2,5 hours | 4 hours |
| Cmax | 3-23 months: 103,8 microg/ml 2-12 years: 113,2 microg/ml |
170,4 microg/ml |
Source: SmpC Invanz
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Bacterial infections |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
No dose adjustment neededGFR 30-50 ml/min/1.73 m2
No dose adjustment neededGFR 10-30 ml/min/1.73 m2
First dose: no dose adjustment, following dosis: 50% of normal single doseGFR < 10 ml/min/1.73 m2
Avoid use.A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Common (1-10%): diarrhea. Diaper dermatitis. Pain at the infusion site. Increase in liver enzyme levels. Decrease in neutrophil count.
Uncommon (0.1-1%): hypertension, hot flashes. Headache. Discoloration of feces, melena. Skin rash, erythema, petechiae. Burning sensation, itching or erythema at the infusion site. Decrease in hemoglobin concentration. Increase in platelet count, increase in prothrombin time and aPTT.
Furthermore, hallucination, altered mental states (such as aggression) have been reported.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| First-generation cephalosporins | ||
|---|---|---|
| J01DB05 | ||
| J01DB04 | ||
| J01DB01 | ||
| J01DB03 | ||
| Second-generation cephalosporins | ||
|---|---|---|
| J01DC04 | ||
| J01DC03 | ||
| J01DC02 | ||
| Third-generation cephalosporins | ||
|---|---|---|
| J01DD08 | ||
| J01DD01 | ||
| J01DD13 | ||
| J01DD52 | ||
| J01DD02 | ||
| J01DD14 | ||
| J01DD04 | ||
| Fourth-generation cephalosporins | ||
|---|---|---|
| J01DE01 | ||
| Monobactams | ||
|---|---|---|
| J01DF01 | ||
| Carbapenems | ||
|---|---|---|
| J01DH51 | ||
| J01DH02 | ||
| MONOBACTAMS | ||
|---|---|---|
| J01DF01 | ||
| Other cephalosporins and penems | ||
|---|---|---|
| J01DI02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Reference
- Merck Sharp & Dohme B.V., SmPC Invanz (EU/1/02/216) Rev 26; 25-10-2022, www.ema.europa.eu
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
